IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

26. November 20:13 Neue Corona-Variante B.1.1.529: Diese US-Aktien sind gefährdet

26. November 21:17 Merck & Co: Neue Studiendaten zur Corona-Pille setzen Aktie unter ...

27. November 07:00 Diese extremen Kryptocoins spalten die Anlegerszene – massive ...

27. November 07:55 Geheim: Die Top-3 im TSI-USA-Ranking!

27. November 08:30 Allianz: Ausverkaufskurse am Freitag – jetzt nachziehen?

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021